Analyst Price Target is $5.00
▲ +194.12% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Can-Fite BioPharma in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 194.12% upside from the last price of $1.70.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Can-Fite BioPharma. This Buy consensus rating has held steady for over two years.
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for cancer and inflammatory diseases. Its product pipeline includes Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.